ABBV vs. AMZN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ABBV and AMZN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ABBV | AMZN |
|---|---|---|
| Company Name | AbbVie Inc. | Amazon.com, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Consumer Discretionary |
| GICS Industry | Biotechnology | Broadline Retail |
| Market Capitalization | 413.71 billion USD | 2,466.23 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | January 2, 2013 | May 15, 1997 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ABBV and AMZN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ABBV | AMZN |
|---|---|---|
| 5-Day Price Return | 6.24% | -5.52% |
| 13-Week Price Return | 12.42% | 1.58% |
| 26-Week Price Return | 23.60% | 11.03% |
| 52-Week Price Return | 36.40% | 9.62% |
| Month-to-Date Return | 6.57% | -3.90% |
| Year-to-Date Return | 30.76% | 6.97% |
| 10-Day Avg. Volume | 6.26M | 45.21M |
| 3-Month Avg. Volume | 5.46M | 45.52M |
| 3-Month Volatility | 24.91% | 33.24% |
| Beta | 0.33 | 1.38 |
Profitability
Return on Equity (TTM)
ABBV
95.59%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
AMZN
23.62%
Broadline Retail Industry
- Max
- 47.53%
- Q3
- 30.86%
- Median
- 16.43%
- Q1
- 10.93%
- Min
- -4.08%
AMZN’s Return on Equity of 23.62% is on par with the norm for the Broadline Retail industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
ABBV
4.00%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
ABBV’s Net Profit Margin of 4.00% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
AMZN
11.06%
Broadline Retail Industry
- Max
- 23.91%
- Q3
- 12.92%
- Median
- 8.50%
- Q1
- 4.49%
- Min
- -1.62%
AMZN’s Net Profit Margin of 11.06% is aligned with the median group of its peers in the Broadline Retail industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
ABBV
15.16%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
ABBV’s Operating Profit Margin of 15.16% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
AMZN
11.02%
Broadline Retail Industry
- Max
- 27.48%
- Q3
- 17.60%
- Median
- 10.79%
- Q1
- 8.10%
- Min
- -4.87%
AMZN’s Operating Profit Margin of 11.02% is around the midpoint for the Broadline Retail industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ABBV | AMZN |
|---|---|---|
| Return on Equity (TTM) | 95.59% | 23.62% |
| Return on Assets (TTM) | 1.76% | 11.42% |
| Net Profit Margin (TTM) | 4.00% | 11.06% |
| Operating Profit Margin (TTM) | 15.16% | 11.02% |
| Gross Profit Margin (TTM) | 71.16% | 50.05% |
Financial Strength
Current Ratio (MRQ)
ABBV
0.72
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
ABBV’s Current Ratio of 0.72 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
AMZN
1.01
Broadline Retail Industry
- Max
- 3.54
- Q3
- 2.57
- Median
- 1.41
- Q1
- 1.20
- Min
- 0.71
AMZN’s Current Ratio of 1.01 falls into the lower quartile for the Broadline Retail industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
ABBV
49.22
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
AMZN
0.14
Broadline Retail Industry
- Max
- 2.01
- Q3
- 1.28
- Median
- 0.64
- Q1
- 0.30
- Min
- 0.00
Falling into the lower quartile for the Broadline Retail industry, AMZN’s Debt-to-Equity Ratio of 0.14 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
ABBV
2.70
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
AMZN
0.62
Broadline Retail Industry
- Max
- 37.34
- Q3
- 21.16
- Median
- 8.60
- Q1
- 2.68
- Min
- -19.29
AMZN’s Interest Coverage Ratio of 0.62 is a critical concern. A value below 1.0 means operating earnings are insufficient to cover interest expenses, indicating severe financial strain and high default risk.
Financial Strength at a Glance
| Symbol | ABBV | AMZN |
|---|---|---|
| Current Ratio (MRQ) | 0.72 | 1.01 |
| Quick Ratio (MRQ) | 0.47 | 0.80 |
| Debt-to-Equity Ratio (MRQ) | 49.22 | 0.14 |
| Interest Coverage Ratio (TTM) | 2.70 | 0.62 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ABBV
2.80%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ABBV’s Dividend Yield of 2.80% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
AMZN
0.00%
Broadline Retail Industry
- Max
- 3.86%
- Q3
- 2.28%
- Median
- 0.36%
- Q1
- 0.00%
- Min
- 0.00%
AMZN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ABBV
362.90%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 362.90%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
AMZN
0.00%
Broadline Retail Industry
- Max
- 123.73%
- Q3
- 65.43%
- Median
- 31.90%
- Q1
- 0.00%
- Min
- 0.00%
AMZN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ABBV | AMZN |
|---|---|---|
| Dividend Yield (TTM) | 2.80% | 0.00% |
| Dividend Payout Ratio (TTM) | 362.90% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ABBV
171.97
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
At 171.97, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
AMZN
32.80
Broadline Retail Industry
- Max
- 50.01
- Q3
- 30.84
- Median
- 17.63
- Q1
- 12.56
- Min
- 5.17
A P/E Ratio of 32.80 places AMZN in the upper quartile for the Broadline Retail industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
ABBV
6.89
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
ABBV’s P/S Ratio of 6.89 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
AMZN
3.63
Broadline Retail Industry
- Max
- 4.38
- Q3
- 3.11
- Median
- 2.13
- Q1
- 0.97
- Min
- 0.23
AMZN’s P/S Ratio of 3.63 is in the upper echelon for the Broadline Retail industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
ABBV
261.01
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
AMZN
6.34
Broadline Retail Industry
- Max
- 10.38
- Q3
- 5.41
- Median
- 3.37
- Q1
- 1.65
- Min
- 0.73
AMZN’s P/B Ratio of 6.34 is in the upper tier for the Broadline Retail industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | ABBV | AMZN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 171.97 | 32.80 |
| Price-to-Sales Ratio (TTM) | 6.89 | 3.63 |
| Price-to-Book Ratio (MRQ) | 261.01 | 6.34 |
| Price-to-Free Cash Flow Ratio (TTM) | 20.86 | 135.15 |